CN101438288A - 谷氨酰胺合成酶的磷酰基转移酶活性的调节 - Google Patents
谷氨酰胺合成酶的磷酰基转移酶活性的调节 Download PDFInfo
- Publication number
- CN101438288A CN101438288A CNA2006800545929A CN200680054592A CN101438288A CN 101438288 A CN101438288 A CN 101438288A CN A2006800545929 A CNA2006800545929 A CN A2006800545929A CN 200680054592 A CN200680054592 A CN 200680054592A CN 101438288 A CN101438288 A CN 101438288A
- Authority
- CN
- China
- Prior art keywords
- compound
- atp
- adenylylation
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2006/000565 WO2007105023A1 (fr) | 2006-03-15 | 2006-03-15 | Modulation de l'activite phosphoryl transferase de la glutamine synthetase |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101438288A true CN101438288A (zh) | 2009-05-20 |
Family
ID=36968970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800545929A Pending CN101438288A (zh) | 2006-03-15 | 2006-03-15 | 谷氨酰胺合成酶的磷酰基转移酶活性的调节 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2008210A1 (fr) |
CN (1) | CN101438288A (fr) |
BR (1) | BRPI0621509A2 (fr) |
WO (1) | WO2007105023A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103709164A (zh) * | 2013-12-04 | 2014-04-09 | 浙江工业大学 | 一种腺嘌呤的合成方法 |
CN109456329A (zh) * | 2018-11-19 | 2019-03-12 | 威海迪素制药有限公司 | 一种泛昔洛韦的制备方法 |
CN113967207A (zh) * | 2021-11-22 | 2022-01-25 | 重庆医科大学 | 4-异硫脲基丁腈盐酸盐在治疗分枝杆菌感染中的应用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2660758A1 (fr) | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Derives de la morpholino pyrimidine utiles dans le traitement de maladies proliferatives |
WO2008130669A1 (fr) * | 2007-04-20 | 2008-10-30 | The Research Foundation Of State University Of New York | Benzimidazoles et compositions pharmaceutiques de ceux-ci |
WO2008134553A1 (fr) * | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Procédés de traitement de maladies associées aux canaux sodiques au moyen de composés bicycliques |
EP2176238B1 (fr) | 2007-07-09 | 2012-04-18 | AstraZeneca AB | Dérivés de morpholino pyrimidine utilisés dans des maladies liées à une kinase mtor et/ou à pi3k |
US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
WO2010116302A1 (fr) * | 2009-04-07 | 2010-10-14 | University Of The Witwatersrand, Johannesburg | Dérivés d'imidazo[1,2-a] pyridine-6-carboxamides, leur utilisation pour le traitement du cancer du côlon et leur procédé de fabrication |
EP2440533B1 (fr) * | 2009-06-12 | 2015-09-23 | Socpra-Sciences Et Génie S.E.C. | Composés se liant à un ribocommutateur guanine et leur utilisation en tant qu'antibiotiques |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
CN104974098A (zh) * | 2015-06-30 | 2015-10-14 | 苏州开元民生科技股份有限公司 | 2,5-二氨基-4,6-二羟基嘧啶盐酸盐的合成方法 |
IL297543A (en) | 2017-11-30 | 2022-12-01 | Arrakis Therapeutics Inc | Nucleic acid-binding photoprobes and their uses |
US10702525B1 (en) * | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
CN111658646B (zh) * | 2020-06-28 | 2021-03-02 | 河南工业大学 | 2,6-双(2-苯并咪唑基)吡啶在制备耐碳青霉烯类铜绿假单胞菌感染药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4076711A (en) * | 1976-04-05 | 1978-02-28 | Schering Corporation | Triazolo [4,5-d]-pyrimidines |
CH630380A5 (de) * | 1977-08-12 | 1982-06-15 | Lonza Ag | Verfahren zur herstellung von l-methotrexat. |
US4565864A (en) * | 1983-06-02 | 1986-01-21 | Riker Laboratories, Inc. | Substituted imidazo[1,2-c]pyrimidines |
IT1215339B (it) * | 1987-01-14 | 1990-02-08 | Co Pharma Corp Srl | Procedimento per la preparazione di 9-(idrossialchil)-ipoxantine |
IT1212140B (it) * | 1987-05-08 | 1989-11-08 | Sig Gla Pharmaceuticals S P A | Processo per la preparazione del 2,4-diammino-6-(1-piperidinil)-piri mi-din-n-ossido. |
WO2003095448A1 (fr) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Derives de pyridinyl amino pyrimidine utilises dans le traitement des troubles de l'hyperproliferation |
US20060142251A1 (en) * | 2002-11-15 | 2006-06-29 | Gunther Harth | Anti-microbial agents derived from methionine sulfoximine analogues |
-
2006
- 2006-03-15 CN CNA2006800545929A patent/CN101438288A/zh active Pending
- 2006-03-15 BR BRPI0621509-2A patent/BRPI0621509A2/pt not_active IP Right Cessation
- 2006-03-15 EP EP06727316A patent/EP2008210A1/fr not_active Withdrawn
- 2006-03-15 WO PCT/IB2006/000565 patent/WO2007105023A1/fr active Application Filing
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103709164A (zh) * | 2013-12-04 | 2014-04-09 | 浙江工业大学 | 一种腺嘌呤的合成方法 |
CN109456329A (zh) * | 2018-11-19 | 2019-03-12 | 威海迪素制药有限公司 | 一种泛昔洛韦的制备方法 |
CN109456329B (zh) * | 2018-11-19 | 2021-03-09 | 迪嘉药业集团有限公司 | 一种泛昔洛韦的制备方法 |
CN113967207A (zh) * | 2021-11-22 | 2022-01-25 | 重庆医科大学 | 4-异硫脲基丁腈盐酸盐在治疗分枝杆菌感染中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2008210A1 (fr) | 2008-12-31 |
WO2007105023A1 (fr) | 2007-09-20 |
BRPI0621509A2 (pt) | 2011-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101438288A (zh) | 谷氨酰胺合成酶的磷酰基转移酶活性的调节 | |
KR100722194B1 (ko) | 피롤로[2,3디]피리미딘 조성물 및 이의 용도 | |
CN102471248B (zh) | 用于递送1,3-丙二磺酸的方法、化合物和组合物 | |
ES2911888T3 (es) | Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos | |
ES2841452T3 (es) | Macrociclos de piridazinona como inhibidores de IRAK y sus usos | |
EP3159340B1 (fr) | Inhibiteur de la tyrosine kinase de bruton | |
JP7328987B2 (ja) | Ii型irak阻害剤としてのヘテロアリール化合物及びその使用 | |
EP3398950B1 (fr) | Nouvel inhibiteur de kinase contre un egfr de type sauvage et un egfr muté | |
CN103596957B (zh) | 作为akt激酶抑制剂的咪唑并哒嗪 | |
CN103237801B (zh) | 对细胞有凋亡诱导活性的喹啉或喹唑啉衍生物 | |
ES2854703T3 (es) | Compuestos de heteroarilo como inhibidores de BTK y usos de los mismos | |
CN105367503A (zh) | 杂芳基化合物和其用途 | |
EP3717462B1 (fr) | Co-cristal d'acide benzoïque et d'un composé de sulfonamide pour le traitement des tumeurs | |
CN1093860C (zh) | 哒嗪并[4,5-b]喹啉5-氧化物衍生物,它们的制备和作为甘氨酸拮抗剂的应用 | |
CN104066734B (zh) | 三唑并[4,5‑d]嘧啶衍生物 | |
ES2821102T3 (es) | Derivados de azaquinazolincarboxamida | |
WO2021115401A1 (fr) | Dérivés hétérocycliques contenant du fluor ayant une structure macrocyclique et leur utilisation | |
IL297714A (en) | Bicyclic kinase inhibitors and their uses | |
CA3219799A1 (fr) | Analogues de triazolo-pyrimidine pour le traitement de maladies liees a l'inhibition de l'helicase recq du syndrome de werner (wrn) | |
CA3214900A1 (fr) | Polytherapies comprenant des inhibiteurs de mytl | |
JP2022505872A (ja) | アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体 | |
CN109305944A (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
CN110343092B (zh) | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 | |
CN111170986A (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
EP3702354B1 (fr) | Composé présentant une activité inhibitrice de kinase erk et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090520 |